Aptamer Group and Neuro-Bio Develop Innovative Alzheimer's Disease Diagnostic Exam
Aptamer Group plc, a leading developer of next-generation synthetic binders for the life science industry, and Neuro-Bio Ltd, a company spearheaded by Baroness Susan Greenfield, have joined forces to create a groundbreaking diagnostic test for Alzheimer's disease. This innovative solution leverages aptamer technology and proteomic analysis to offer a rapid, convenient, and patient-friendly approach.
The test under development is a blood-based early detection test for Alzheimer's disease, utilising aptamer-based proteomic biomarkers. Aptamers, short DNA or RNA molecules, can bind to specific proteins, making them promising tools for detecting neurodegenerative disease biomarkers. The test aims to identify proteomic signatures in plasma that correlate with Alzheimer's risk, potentially enabling earlier and less invasive diagnosis compared to traditional methods relying on cerebrospinal fluid or neuroimaging.
Recent updates indicate that the diagnostic test is still under active development, with strategic agreements in place, such as the royalty agreement with Neuro-Bio, featuring a blended royalty rate of 11.1% on the first 166 million GBP of sales, and 5% thereafter for a 15-year term. However, it is not yet a fully commercialized or regulatory-approved product.
The collaboration between Aptamer Group and Neuro-Bio involves the unique technical expertise of both companies. Neuro-Bio, led by Baroness Susan Greenfield, discovered and validated the novel biomarker, an early disease biomarker with the potential to detect the disease before symptoms arise. Neuro-Bio is also developing a treatment targeting this biomarker.
The partners are working on clinically validating the new test format, and Neuro-Bio's progress has been met with excitement by Baroness Susan Greenfield, who believes that the combination of Aptamer's technical talent and Neuro-Bio's insights into Alzheimer's disease holds the promise of a real breakthrough.
Future developments likely include further clinical validation of the aptamer-based proteomic signatures in diverse populations to confirm diagnostic accuracy and robustness, regulatory submissions and approvals, potential integration of AI and machine learning to enhance detection algorithms, and the possibility of expanding the platform to detect other neurodegenerative diseases or dementia subtypes.
The Alzheimer's disease diagnostic market is valued at 8.3 billion USD and is expected to rise to 19.6 billion USD by 2029. This partnership between Aptamer Group and Neuro-Bio has the potential to transform the diagnostic market for Alzheimer's disease by increasing accessibility and accelerating time-to-diagnosis.
As the collaboration progresses, both parties look forward to a closer relationship, with Neuro-Bio's team expressing enthusiasm about working with Aptamer Group researchers. The current status of the Alzheimer's disease diagnostic test being developed by Aptamer Group plc and Neuro-Bio Ltd is that it is an early detection test leveraging proteomic patterns and aptamer technology, with recent progress including a royalty agreement and ongoing development as of mid-2025.
[1] Aptamer Group press release, 2025. [2] Neuro-Bio Ltd press release, 2025. [3] Aptamer Group website, 2025. [4] Clinical validation study, ongoing. [5] Large-scale biomarker study in Alzheimer's, ongoing.
- The collaboration between Aptamer Group and Neuro-Bio aims to revolutionize the healthcare industry, particularly in the field of digital health, by developing a groundbreaking diagnostic test for Alzheimer's disease that leverages aptamer technology and proteomic analysis.
- The diagnostic test, still under development, utilizes aptamer-based proteomic biomarkers to offer a rapid, convenient, and patient-friendly early detection test for Alzheimer's disease, potentially identifying proteomic signatures in plasma that can predict Alzheimer's risk.
- The partnership also extends to the exploration of mental health and neurological disorders, with Neuro-Bio developing a treatment targeting the novel biomarker discovered by Baroness Susan Greenfield, and the possibility of expanding the platform to detect other neurodegenerative diseases or dementia subtypes in the future.
